PE20230304A1 - Derivados de glucagon como agentes hipoglucemicos y antiobesidad - Google Patents
Derivados de glucagon como agentes hipoglucemicos y antiobesidadInfo
- Publication number
- PE20230304A1 PE20230304A1 PE2022001996A PE2022001996A PE20230304A1 PE 20230304 A1 PE20230304 A1 PE 20230304A1 PE 2022001996 A PE2022001996 A PE 2022001996A PE 2022001996 A PE2022001996 A PE 2022001996A PE 20230304 A1 PE20230304 A1 PE 20230304A1
- Authority
- PE
- Peru
- Prior art keywords
- glucagon
- present
- hypoglycemic
- obesity agents
- hypoglycemia
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 5
- 230000002218 hypoglycaemic effect Effects 0.000 title abstract 3
- 239000000883 anti-obesity agent Substances 0.000 title abstract 2
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 229940125710 antiobesity agent Drugs 0.000 title abstract 2
- 229940126904 hypoglycaemic agent Drugs 0.000 title abstract 2
- 102000051325 Glucagon Human genes 0.000 abstract 2
- 108060003199 Glucagon Proteins 0.000 abstract 2
- 208000013016 Hypoglycemia Diseases 0.000 abstract 2
- 229960004666 glucagon Drugs 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 1
- 102100040890 Glucagon receptor Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000000704 physical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invencion se refiere a un nuevo peptido derivado del glucagon y a una composicion para la prevencion o el tratamiento de hipoglucemia, que contiene el nuevo peptido derivado del glucagon como principio activo. El derivado de glucagon de acuerdo con la presente invencion tiene propiedades fisicas mejoradas debido al cambio en el punto isoelectrico (pI) mientras que es capaz de mantener una actividad en los receptores del glucagon y, por tanto, puede mejorar la conformidad del paciente cuando se usa como un agente hipoglucemico y tambien es adecuado para la administracion en combinacion con otros agentes antiobesidad. Por consiguiente, el derivado de glucagon de acuerdo con la presente invencion se puede usar de manera eficaz para la prevencion y el tratamiento de la hipoglucemia y la obesidad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140193800 | 2014-12-30 | ||
| PCT/KR2015/014422 WO2016108586A1 (ko) | 2014-12-30 | 2015-12-30 | 안정성이 증가된 글루카곤 유도체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230304A1 true PE20230304A1 (es) | 2023-02-13 |
Family
ID=56284642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001996A PE20230304A1 (es) | 2014-12-30 | 2015-12-30 | Derivados de glucagon como agentes hipoglucemicos y antiobesidad |
| PE2017001168A PE20171154A1 (es) | 2014-12-30 | 2015-12-30 | Derivados de glucagon con estabilidad mejorada |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001168A PE20171154A1 (es) | 2014-12-30 | 2015-12-30 | Derivados de glucagon con estabilidad mejorada |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11135271B2 (es) |
| EP (2) | EP3241841A4 (es) |
| JP (2) | JP6797122B2 (es) |
| KR (1) | KR102291020B1 (es) |
| CN (1) | CN107636009B (es) |
| AR (1) | AR103322A1 (es) |
| AU (1) | AU2015372818A1 (es) |
| CL (1) | CL2017001718A1 (es) |
| CO (1) | CO2017006308A2 (es) |
| CR (1) | CR20170293A (es) |
| DO (1) | DOP2017000156A (es) |
| EA (1) | EA035527B1 (es) |
| EC (1) | ECSP17040923A (es) |
| ES (1) | ES2976562T3 (es) |
| GT (1) | GT201700150A (es) |
| HK (1) | HK1248713A1 (es) |
| IL (2) | IL253206B (es) |
| MA (1) | MA40709B1 (es) |
| MX (1) | MX2017008569A (es) |
| MY (1) | MY185334A (es) |
| PE (2) | PE20230304A1 (es) |
| PH (1) | PH12017501222B1 (es) |
| SG (1) | SG11201705376SA (es) |
| TN (1) | TN2017000271A1 (es) |
| TW (1) | TW201639878A (es) |
| UA (1) | UA126960C2 (es) |
| WO (1) | WO2016108586A1 (es) |
| ZA (1) | ZA201705015B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102291020B1 (ko) | 2014-12-30 | 2021-08-20 | 한미약품 주식회사 | 안정성이 증가된 글루카곤 유도체 |
| DK3322437T5 (da) * | 2015-06-30 | 2024-10-07 | Hanmi Pharmaceutical Co Ltd | Glukagonderivat og en sammensætning omfattende et langtidsvirkende konjugat af samme |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| PE20250556A1 (es) | 2015-12-31 | 2025-02-24 | Hanmi Pharmaceutical Co Ltd | Agonista triple de receptores de glucagon/glp-1/gip |
| CA3029518A1 (en) * | 2016-06-29 | 2018-01-04 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof |
| US20200230250A1 (en) | 2017-02-03 | 2020-07-23 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of a physiologically active material and use thereof |
| EA202091239A1 (ru) * | 2017-12-22 | 2020-09-09 | Ханми Фарм. Ко., Лтд. | Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение |
| US20210030847A1 (en) * | 2018-01-23 | 2021-02-04 | Xeris Pharmaceuticals, Inc. | Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon |
| JP2022514835A (ja) * | 2018-12-21 | 2022-02-16 | ハンミ ファーマシューティカル カンパニー リミテッド | インスリン及びグルカゴンを含む薬学組成物 |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| MX2022014669A (es) | 2020-05-22 | 2023-02-13 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de conjugado de derivado de glucagon de accion prolongada. |
| BR112023000515A2 (pt) * | 2020-07-15 | 2023-03-21 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica e seu uso |
| IL305549A (en) | 2021-04-09 | 2023-10-01 | Hanmi Pharm Ind Co Ltd | Pharmaceutical composition for the prevention or treatment of chronic kidney disease including a glucagon derivative |
| KR20230095666A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 물질 및 이의 용도 |
| CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| GB9423277D0 (en) | 1994-11-18 | 1995-01-11 | Univ Nottingham | Pulsed laser deposition of coatings |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| EP2275117B1 (en) | 2001-07-31 | 2016-10-26 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
| HRP20050683A2 (en) | 2003-03-19 | 2006-07-31 | Eli Lilly And Company | Polyethylene glycol linked glp-1 compounds |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| RU2352583C2 (ru) | 2003-11-13 | 2009-04-20 | Ханми Фарм. Инд. Ко., Лтд. | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ |
| WO2007124461A2 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | Glp-1 compounds |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| WO2008086086A2 (en) * | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| KR20100049032A (ko) | 2007-06-19 | 2010-05-11 | 오츠카 가가쿠 가부시키가이샤 | 당사슬 부가 ｇｌｐ―１ 펩티드 |
| CN101868476B (zh) | 2007-09-05 | 2015-02-25 | 诺沃-诺迪斯克有限公司 | 胰高血糖素样肽-1衍生物及其制药用途 |
| CN101983066B (zh) | 2008-01-30 | 2016-06-29 | 印第安那大学科技研究公司 | 基于酯的胰岛素前药 |
| BRPI0915282A2 (pt) | 2008-06-17 | 2017-02-07 | Univ Indiana Res & Tech Corp | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade |
| KR20110039230A (ko) * | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| PE20120914A1 (es) | 2009-06-16 | 2012-08-22 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip |
| DK2454282T3 (en) | 2009-07-13 | 2015-05-04 | Zealand Pharma As | acetylated glucagonanaloger |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| US8703701B2 (en) * | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| MX342409B (es) * | 2010-01-20 | 2016-09-28 | Zealand Pharma As | Tratamiento de enfermedades cardiacas. |
| CN102918055B (zh) | 2010-03-26 | 2017-03-29 | 诺沃—诺迪斯克有限公司 | 新的胰高血糖素类似物 |
| EP2568993A4 (en) | 2010-05-13 | 2014-02-19 | Univ Indiana Res & Tech Corp | GLUCAGON SUPERFAMILY PEPTIDES WITH G-PROTEIN-COUPLED RECEPTOR ACTIVITY |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| KR20130132931A (ko) | 2010-12-22 | 2013-12-05 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체 활성을 나타내는 글루카곤 유사체들 |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| AU2012255119B2 (en) | 2011-05-18 | 2017-04-20 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| DK3878859T5 (da) * | 2011-06-10 | 2024-06-10 | Hanmi Science Co Ltd | Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse |
| SI2721062T1 (sl) * | 2011-06-17 | 2019-03-29 | Hanmi Science Co., Ltd. | Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| BR112014007124A2 (pt) * | 2011-11-17 | 2017-06-13 | Univ Indiana Res & Tech Corp | superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide |
| CA2877127A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Analogs of glucagon exhibiting gip receptor activity |
| ES2602486T3 (es) | 2012-06-21 | 2017-02-21 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran actividad de receptor de GIP |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
| KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| MY168536A (en) | 2012-11-06 | 2018-11-12 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin fc region |
| CA2891929C (en) | 2012-11-20 | 2022-07-19 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| AU2013347975B2 (en) | 2012-11-20 | 2018-07-26 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| MX2015008114A (es) | 2012-12-21 | 2015-11-06 | Sanofi Sa | Derivados de exendina-4. |
| SI2986313T1 (sl) * | 2013-04-18 | 2019-09-30 | Novo Nordisk A/S | Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo |
| EP3033355A1 (en) | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| WO2016049190A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| KR102291020B1 (ko) | 2014-12-30 | 2021-08-20 | 한미약품 주식회사 | 안정성이 증가된 글루카곤 유도체 |
| DK3322437T5 (da) * | 2015-06-30 | 2024-10-07 | Hanmi Pharmaceutical Co Ltd | Glukagonderivat og en sammensætning omfattende et langtidsvirkende konjugat af samme |
| TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| PE20250556A1 (es) | 2015-12-31 | 2025-02-24 | Hanmi Pharmaceutical Co Ltd | Agonista triple de receptores de glucagon/glp-1/gip |
-
2015
- 2015-12-30 KR KR1020150189532A patent/KR102291020B1/ko active Active
- 2015-12-30 TN TN2017000271A patent/TN2017000271A1/en unknown
- 2015-12-30 EP EP15875680.9A patent/EP3241841A4/en not_active Withdrawn
- 2015-12-30 PE PE2022001996A patent/PE20230304A1/es unknown
- 2015-12-30 PH PH1/2017/501222A patent/PH12017501222B1/en unknown
- 2015-12-30 ES ES19172184T patent/ES2976562T3/es active Active
- 2015-12-30 CR CR20170293A patent/CR20170293A/es unknown
- 2015-12-30 SG SG11201705376SA patent/SG11201705376SA/en unknown
- 2015-12-30 UA UAA201707040A patent/UA126960C2/uk unknown
- 2015-12-30 HK HK18104685.2A patent/HK1248713A1/en unknown
- 2015-12-30 US US15/540,729 patent/US11135271B2/en active Active
- 2015-12-30 WO PCT/KR2015/014422 patent/WO2016108586A1/ko not_active Ceased
- 2015-12-30 EA EA201791333A patent/EA035527B1/ru not_active IP Right Cessation
- 2015-12-30 EP EP19172184.4A patent/EP3575314B1/en active Active
- 2015-12-30 MX MX2017008569A patent/MX2017008569A/es unknown
- 2015-12-30 MA MA40709A patent/MA40709B1/fr unknown
- 2015-12-30 AR ARP150104340A patent/AR103322A1/es unknown
- 2015-12-30 JP JP2017535417A patent/JP6797122B2/ja active Active
- 2015-12-30 MY MYPI2017000967A patent/MY185334A/en unknown
- 2015-12-30 AU AU2015372818A patent/AU2015372818A1/en not_active Abandoned
- 2015-12-30 TW TW104144427A patent/TW201639878A/zh unknown
- 2015-12-30 PE PE2017001168A patent/PE20171154A1/es unknown
- 2015-12-30 CN CN201580077186.3A patent/CN107636009B/zh active Active
-
2017
- 2017-06-27 IL IL253206A patent/IL253206B/en unknown
- 2017-06-27 CO CONC2017/0006308A patent/CO2017006308A2/es unknown
- 2017-06-28 GT GT201700150A patent/GT201700150A/es unknown
- 2017-06-28 CL CL2017001718A patent/CL2017001718A1/es unknown
- 2017-06-28 EC ECIEPI201740923A patent/ECSP17040923A/es unknown
- 2017-06-29 DO DO2017000156A patent/DOP2017000156A/es unknown
- 2017-07-24 ZA ZA2017/05015A patent/ZA201705015B/en unknown
-
2020
- 2020-08-28 JP JP2020144259A patent/JP7079301B2/ja active Active
-
2021
- 2021-03-09 IL IL281375A patent/IL281375B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230304A1 (es) | Derivados de glucagon como agentes hipoglucemicos y antiobesidad | |
| CL2018000684A1 (es) | Moduladores de la proteína de núcleo de la hepatitis b. | |
| PE20180449A1 (es) | Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo | |
| ECSP19021223A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| CR20120345A (es) | Derivados de 3-hidroxi-5-arilisotiazol novedosos | |
| UA118558C2 (uk) | Пептидна сполука | |
| CR20160367A (es) | Compuesto heterocíclico fusionado | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| CL2016002372A1 (es) | Cenicriviroc para el tratamiento de la fibrosis. | |
| DOP2016000233A (es) | MODULADORES ALOSTÉRICOS DE PROTElNA NÚCLEO DE HEPATITIS B | |
| CO2019009215A2 (es) | Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| CL2017002031A1 (es) | Formulación en polvo nasal para el tratamiento de hipoglicemia | |
| BR112018067731A2 (pt) | coagonistas de glucagon e glp-1 para o tratamento de obesidade | |
| CR20170314A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| AR128158A2 (es) | Compuesto heterocíclico | |
| AR103323A1 (es) | Derivados de glucagón | |
| CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
| CL2017001843A1 (es) | Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2. | |
| AR082278A1 (es) | Vacunas de enterovirus para prevenir o tratar diabetes tipo 1 (iii) | |
| UY35650A (es) | Compuesto heterocíclico | |
| CL2017001680A1 (es) | Composición farmacéutica para el tratamiento de enfermedades gastrointestinales | |
| MX2018004779A (es) | Uso terapeutico de una solucion oftalmica acuosa esteril. | |
| CL2022002644A1 (es) | Derivados de glucagón con estabilidad mejorada | |
| CL2022002646A1 (es) | Derivados de glucagón con estabilidad mejorada |